Hikma Pharmaceuticals Plc
(LSE) HIK
Hikma Pharmaceuticals Plc Financials at a Glance
Market Cap
£3.40BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Revenue (TTM)
$6.48B
Net Income (TTM)
$761.79M
EPS (TTM)
£1.38
P/E Ratio
11.66
Dividend
£0.62
Beta (Volatility)
0.05 (Low)
Dividend
£0.62
Beta (Volatility)
0.05 (Low)
Price
£16.03
Volume
357,901
Open
£16.23
Price
£16.03
Volume
357,901
Open
£16.23
Previous Close
£16.15
Daily Range
£16.00 - £16.29
52-Week Range
£11.87 - £20.52
Estimated Earnings Date
Aug 6, 2026
Dividend
£0.62
Beta (Volatility)
0.05 (Low)
Price
£16.03
Volume
357,901
Open
£16.23
Previous Close
£16.15
Daily Range
£16.00 - £16.29
52-Week Range
£11.87 - £20.52
Estimated Earnings Date
Aug 6, 2026
HIK News
Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Hikma Pharmaceuticals Plc
Industry
Pharmaceuticals
Sector
Health CareEmployees
9,400
CEO
Riad Mishlawi
Website
www.hikma.comHeadquarters
London, GL W1S 2HR, GB
HIK Financials
Key Financial Metrics (TTM)
Gross Margin
41.35%
Operating Margin
16.81%
Net Income Margin
12.00%
Return on Equity
15.83%
Return on Capital
13.81%
Return on Assets
7.10%
Earnings Yield
8.58%
Dividend Yield
3.83%
Payout Ratio
45.16%
Stock Overview
Market Cap
£3.40BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Shares Outstanding
210.37M
Volume
357.90K
Avg. Volume
860.93K
Financials (TTM)
Gross Profit
$2.80B
Operating Income
$1.18B
EBITDA
$1.46B
Operating Cash Flow
$953.94M
Capital Expenditure
-$360.38M
Free Cash Flow
$593.56M
Cash & ST Invst.
$354.13M
Total Debt
$1.60B
Hikma Pharmaceuticals Plc Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$1.70B
+17.3%
Gross Profit
$673.22M
-2.7%
Gross Margin
39.62%
N/A
Market Cap
£3.40BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
N/A
Market Cap/Employee
£357.62K
N/A
Employees
9,500
N/A
Net Income
$164.79M
+179.3%
EBITDA
$410.96M
+19.1%
Quarterly Fundamentals
Total Cash
$354.13M
+72.7%
Total Debt
$1.60B
+34.7%
Accounts Receivable
$1.08B
+36.8%
Inventory
$1.11B
+24.2%
Long Term Debt
$1.49B
+44.7%
Short Term Debt
$114.00M
-29.2%
Return on Assets
7.10%
N/A
Return on Invested Capital
13.38%
N/A
Free Cash Flow
$101.56M
-66.3%
Operating Cash Flow
$228.94M
-40.7%